How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

Abstract

P-glycoprotein (ABCB1), multidrug resistance protein-1 (ABCC1) and breast cancer resistance protein (ABCG2) belong to the ATP-binding cassette (ABC) superfamily of proteins that play an important physiological role in protection of the body from toxic xenobiotics and endogenous metabolites. Beyond this, these transporters determine the toxicity profile of many drugs, and confer multidrug resistance (MDR) in cancer cells associated with a poor treatment outcome of cancer patients. It has long been hypothesized that inhibition of ABC drug efflux transporters will increase drug accumulation and thereby overcome MDR, but until now no approved inhibitor of these transporters is available in the clinic. In this review we present molecular strategies to overcome this type of drug resistance and discuss for each of these strategies their promising value or indicate underlying reasons for their limited success.

Keywords

Breast cancer resistance protein / ATP-binding cassette transporters / multidrug resistance / multidrug resistance protein

References

[1] Binkhathlan Z.P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives..Curr Cancer Drug Targets2013;13:326-46

[2] Longley DB.Molecular mechanisms of drug resistance..J Pathol2005;205:275-92

[3] Tiwari AK,Dai CL,Chen ZS.Revisiting the ABCs of multidrug resistance in cancer chemotherapy..Curr Pharm Biotechnol2011;12:570-94

[4] Gottesman MM,Bates SE.Multidrug resistance in cancer: role of ATP-dependent transporters..Nat Rev Cancer2002;2:48-58

[5] Zahreddine H.Mechanisms and insights into drug resistance in cancer..Front Pharmacol2013;4:28 PMCID:PMC3596793

[6] Cree IA.Molecular chess? Hallmarks of anti-cancer drug resistance..BMC Cancer2017;17:1-8

[7] Dean M,Allikmets R.The human ATP-binding cassette (ABC) transporter superfamily..Genome Res2001;11:1156-66

[8] Vasiliou V,Nebert DW.Human ATP-binding cassette (ABC) transporter family..Hum Genomics2009;3:281-90 PMCID:PMC2752038

[9] Li W,Assaraf YG,Xu X,Yang DH.Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies..Drug Resist Updat2016;27:14-29

[10] Mo W.Human ABCG2: structure, function, and its role in multidrug resistance..Int J Biochem Mol Biol2012;3:1-27

[11] Zhao Z,Johnsen R.ATP-binding cassette protein E is involved in gene transcription and translation in Caenorhabditis elegans..Biochem Biophys Res Commun2004;323:104-11

[12] Bisbal C,Silhol M,Salehzada T.Cloning and characterization of a RNAse L inhibitor. A new component of the interferon-regulated 2-5A pathway..J Biol Chem1995;270:13308-17

[13] Marton MJ,Qiu H,Hinnebusch AG.Evidence that GCN1 and GCN20, translational regulators of GCN4, function on elongating ribosomes in activation of eIF2alpha kinase GCN2..Mol Cell Biol1997;17:4474-89 PMCID:PMC232301

[14] Tyzack JK,Belsham GJ.ABC50 interacts with eukaryotic initiation factor 2 and associates with the ribosome in an ATP-dependent manner..J Biol Chem2000;275:34131-9

[15] Sharom FJ.ABC multidrug transporters: structure, function and role in chemoresistance..Pharmacogenomics2007;9:105-27

[16] Cinci L,Bigagli E,Paccosi S,Guasti D.Development and characterization of an in vitro model of colorectal adenocarcinoma with MDR phenotype..Cancer Med2016;5:1279-91 PMCID:PMC4924386

[17] Pallis M.P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway..Blood2000;95:2897-904

[18] Zhang F,Wang Z,Tian R,Yang Y.P-glycoprotein associates with Anxa2 and promotes invasion in multidrug resistant breast cancer cells..Biochem Pharmacol2014;87:292-302

[19] van de Ven R,van der Heijden JW,de Gruijl TD,Scheper RJ.ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer..J Leukoc Biol2009;86:1075-87

[20] Juliano RL.A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants..Biochim Biophys Acta1976;455:152-62

[21] Ferry D,Cullen M.P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is alloserically coupled to a vinca-alkaloid-selective binding site..Biochem Biophys Res Commun1992;188:440-5

[22] Gottesman MM,Xia D.Structure of a multidrug transporter: crystal structures of a mammalian multidrug efflux pump bound to peptide inhibitors may reveal drug binding sites..Nat Biotechnol2009;27:546-7 PMCID:PMC3392087

[23] Ueda K,Gottesman MM.Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine..Proc Natl Acad Sci U S A1987;84:3004-8 PMCID:PMC304789

[24] Aller SG,Ward A,Chittaboina S,Harrell PM,Zhang Q,Chang G.Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding..Science2009;323:1718-22 PMCID:PMC2720052

[25] Loo TW,Clarke DM.Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein..J Biol Chem2003;278:39706-10

[26] Pajeva IK.Structure-activity relationships of tariquidar analogs as multidrug resistance modulators..AAPS J2009;11:435 PMCID:PMC2758111

[27] Thiebaut F,Hamada H,Pastan I.Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues..Proc Natl Acad Sci U S A1987;84:7735-8 PMCID:PMC299375

[28] Cordon-Cardo C,Boccia J,Bertino JR.Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues..J Histochem Cytochem1990;38:1277-87

[29] Anwar-Mohamed A.P-glycoprotein effects on drugs pharmacokinetics and drug-drug-interactions and their clinical implications..Libyan J Pharm Clin Pharmacol2012;1:48154

[30] Sharom FJ.The P-glycoprotein multidrug transporter..Essays Biochem2011;50:161

[31] Baldini N,Barbanti-Bròdano G,Maurici D,Bertoni F,Sottili S,Serra M.Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome..N Engl J Med1995;333:1380-5

[32] Abolhoda A,Ross H,Burt M.Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin..Clin Cancer Res1999;5:3352-6

[33] Gregorcyk S,Brandt D,Singer G.P-glycoprotein expression as a predictor of breast cancer recurrence..Ann Surg Oncol1996;3:8-14

[34] McLornan DP,Johnston P.Molecular mechanisms of drug resistance in acute myeloid leukaemia..Expert Opin Drug Metab Toxicol2007;3:363-77

[35] Xia CQ.Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation..Mol Pharmacol2012;82:1008

[36] Choi JH,Joo HJ,Yi JW,Cho YK,Lee KB.Expression of multidrug resistance-associated protein1, P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection..Br J Cancer2002;86:1578-85 PMCID:PMC2746581

[37] Gao Y,Shen JK,Choy E,Harmon D,Hornicek FJ.Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray..J Orthop Res2016;34:1606-12

[38] Brozek J,Płoszyńska A,Witkowski JM.P-glycoprotein activity predicts outcome in childhood acute lymphoblastic leukemia..J Pediatr Hematol Oncol2009;31:493-9

[39] Steinbach D.ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?.Leukemia2007;21:1172

[40] Broxterman HJ,Feller N,Währer DC,Schoester M,Pinedo HM,Schuurhuis GJ.Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity..Blood1996;87:4809-16

[41] Cole S,Gerlach J,Grant C,Stewart A,Duncan A.Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line..Science1992;258:1650

[42] Flens MJ,van der Valk P,Schroeijers AB,van der Groep P,Meijer CJ.Tissue distribution of the multidrug resistance protein..Am J Pathol1996;148:1237-47

[43] Kourti M,Gombakis N,Tzimagiorgis G,Koliouskas D.Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia..Int J Hematol2007;86:166-73

[44] Bakos E.Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1)..Pflugers Arch2007;453:621-41

[45] Rao VV,Bardgett ME,Finch RA,Piwnica-Worms D.Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier..Proc Natl Acad Sci U S A1999;96:3900-5 PMCID:PMC22392

[46] Bréchot JM,Fajac A,Bernaudin JF.Different pattern of MRP localization in ciliated and basal cells from human bronchial epithelium..J Histochem Cytochem1998;46:513-7

[47] Leslie EM,Cole SP.Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense..Toxicol Appl Pharmacol2005;204:216-37

[48] Wijnholds J,van Leusden MR,Zaman GJ,Beijnen JH,Krimpenfort P.Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein..Nat Med1997;3:1275-9

[49] Lorico A,Finch RA,Flavell RA.Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione..Cancer Res1997;57:5238-42

[50] Renes J,Nienhuis EF,Müller M.ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1..Br J Pharmacol1999;126:681-8 PMCID:PMC1565864

[51] Jedlitschky G,Buchholz U,Kurz G.Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump..Cancer Res1996;56:988

[52] Bakos é,Szakács G,Welker E,de Haas M,Borst P,Sarkadi B.Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain..J Biol Chem1998;273:32167-75

[53] Westlake CJ,Deeley RG.Role of the NH(2)-terminal membrane spanning domain of multidrug resistance protein 1/ABCC1 in protein processing and trafficking..Mol Biol Cell2005;16:2483-92 PMCID:PMC1087251

[54] Yang Y,Zhang JT.Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1..J Biol Chem2002;277:44268-77

[55] Chen Q,Li L.The amino terminus of the human multidrug resistance transporter ABCC1 has a U-shaped folding with a gating function..J Biol Chem2006;281:31152-63

[56] Yang Y,Zhang JT.Role of transmembrane segment 5 and extracellular loop 3 in the homodimerization of human ABCC1..Biochemistry2010;49:10854-61 PMCID:PMC3095655

[57] Sodani K,Kathawala RJ.Multidrug resistance associated proteins in multidrug resistance..Chin J Cancer2012;31:58-72 PMCID:PMC3777468

[58] Ween MP,Oehler MK.The role of ABC transporters in ovarian cancer progression and chemoresistance..Crit Rev Oncol Hematol2015;96:220-56

[59] Hipfner DR,Cole SP.Structural, mechanistic and clinical aspects of MRP1..Biochim Biophys Acta1999;1461:359-76

[60] Haber M,Bordow SB,Cohn SL,Marshall GM.Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma..J Clin Oncol2006;24:1546-53

[61] Li XQ,Shi SB,Yu LC.Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy..Int J Biol Markers2009;24:230-7

[62] Filipits M,Rudas M,Lax S,Pirker R,Hausmaninger H,Samonigg H.Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group..J Clin Oncol2005;23:1161-8

[63] Mao Q.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport - an update..AAPS J2015;17:65-82 PMCID:PMC4287283

[64] Taipalensuu J,Lindberg G,Sjöqvist F,Garberg P,Lundgren B.Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers..J Pharmacol Exp Ther2001;299:164-70

[65] Merino G,Pulido MM,Schinkel AH.Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion..Drug Metab Dispos2006;34:690

[66] Seamon JA,Emanuel S,Ambudkar SV,Butler J,Greenberger LM.Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor..Mol Cancer Ther2006;5:2459

[67] Yamagata T,Morishita M,Benameur H.Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients..Drug Metab Dispos2007;35:1142

[68] Tanaka Y,Maeda K.Quantitative analysis of the ABCG2 c.421C>A polymorphism effect on in vivo transport activity of breast cancer resistance protein (BCRP) using an intestinal absorption model..J Pharm Sci2015;104:3039-48

[69] Kruijtzer CM,Rosing H,Schot M,Paul EM.Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918..J Clin Oncol2002;20:2943-50

[70] Staud F.Breast cancer resistance protein (BCRP/ABCG2)..Int J Biochem Cell Biol2005;37:720-5

[71] Clark R,Callaghan R.Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter..Br J Pharmacol2006;149:506-15 PMCID:PMC2014674

[72] Giri N,Shaik N,Chen Y.Substrate-dependent breast cancer resistance protein (BCRP1/ABCG2)-mediated interactions: consideration of multiple binding sites in in vitro assay design..Drug Metab Dispos2009;37:560-70 PMCID:PMC2680510

[73] Muenster U,Ickenroth K.Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions..Pharm Res2008;25:2320-6

[74] Hazai E.Homology modeling of breast cancer resistance protein (ABCG2)..J Struct Biol2008;162:63-74

[75] Kage K,Sugiyama T,Ishikawa E,Sugimoto Y.Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization..Int J Cancer2002;97:626-30

[76] Mo W.Oligomerization of human ATP-binding cassette transporters and its potential significance in human disease..Expert Opin Drug Metab Toxicol2009;5:1049-63

[77] Ni Z,Rosenberg MF.Structure and function of the human breast cancer resistance protein (BCRP/ABCG2)..Curr Drug Metab2010;11:603-17 PMCID:PMC2950214

[78] Diestra JE,Català I,Schellens JHM,Germà-Lluch JR.Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material..J Pathol2002;198:213-9

[79] Damiani D,Calistri E,Chiarvesio A,Cavallin M.The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype..Haematologica2006;91:825-8

[80] Plasschaert SL,de Bont ES,Morisaki K,Scheffer GL,Vellenga E.The role of breast cancer resistance protein in acute lymphoblastic leukemia..Clin Cancer Res2003;9:5171-7

[81] Stam RW,den Boer ML,Janka-Schaub GE,Pieters R.Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein..Leukemia2003;18:78-83

[82] Robey RW,Polgar O,Fetsch P,Bates SE.ABCG2: a perspective..Adv Drug Deliv Rev2009;61:3-13 PMCID:PMC3105088

[83] Li-Blatter X,Seelig A.P-glycoprotein-ATPase modulation: the molecular mechanisms..Biophys J2012;102:1383-93 PMCID:PMC3309411

[84] Maki N,Ghosh P.Allosteric modulation bypasses the requirement for ATP hydrolysis in regenerating low affinity transition state conformation of human P-glycoprotein..J Biol Chem2006;281:10769-77

[85] Romsicki Y.The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter..Biochemistry1999;38:6887-96

[86] Aliabadi HM,Mahdipoor P,Uludağ H.Effective down-regulation of breast cancer resistance protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers..Eur J Pharm Biopharm2012;81:33-42

[87] Gomes MJ,Martins S.Delivery of siRNA silencing P-gp in peptide-functionalized nanoparticles causes efflux modulation at the blood-brain barrier..Nanomedicine (Lond).2017;doi:10.2217/nnm-2017-0023.

[88] Fisher M,Van Aerschot A,Juliano RL.Inhibition of MDR1 expression with altritol-modified siRNAs..Nucleic Acids Res2007;35:1064-74 PMCID:PMC1851637

[89] Lam JK,Zhang Y.siRNA versus miRNA as therapeutics for gene silencing..Mol Ther Nucleic Acids2015;4:e252

[90] Cuiffo BG,Bell GW,Orso F,Bhasin MK,Hanson SE,El-Ashry D,Polyak K,Mariani O,Vincent-Salomon A,Karnoub AE.MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis..Cell Stem Cell2014;15:762-74

[91] Broekman F,Peters GJ.Tyrosine kinase inhibitors: multi-targeted or single-targeted?.World J Clin Oncol2011;2:80-93

[92] Liu Y,Zhang J,Zhao Y,Han B,Jiang L.The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China..Clin Respir J2014;8:206-12

[93] Na F,Deng L,Zhou L,Yu M,Xue J.Continuation of tyrosine kinase inhibitor is associated with survival benefit in NSCLC patients with exon 19 deletion after solitary progression..J Cancer2017;8:3682-8 PMCID:PMC5688921

[94] Zhang J,Gray NS.Targeting cancer with small molecule kinase inhibitors..Nat Rev Cancer2009;9:28-39

[95] Wu P,Clausen MH.FDA-approved small-molecule kinase inhibitors..Trends Pharmacol Sci2015;36:422-39

[96] Rask-Andersen M,Fabbro D.Advances in kinase targeting: current clinical use and clinical trials..Trends Pharmacol Sci2014;35:604-20

[97] Kathawala RJ,Ashby CR.The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade..Drug Resist Updat2015;18:1-17

[98] List AF,Willman CL,Persons DL,Dorr R,Hynes HE,Shurafa M.Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study..Blood2001;98:3212-20

[99] Szakács G,Ludwig JA,Gottesman MM.Targeting multidrug resistance in cancer..Nat Rev Drug Discov2006;5:219-34

[100] Callaghan R,Bebawy M.Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?.Drug Metab Dispos2014;42:623-31

[101] List AF,Willman CL,Slovak ML,Dakhil SR.Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase..Blood2002;100:1910-2

[102] Abraham J,Wilson R,Rutt A,Robey R,Goldspiel B,Van Tellingen O,Fojo T.A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine..Clin Cancer Res2009;15:3574-82

[103] Gerrard G,Baker R,Potter M,Ethell M,Burgess M,Ganeshaguru K.Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine..Haematologica2004;89:782-90

[104] Sandler A,de Alwis DP,Green L,Chaudhary A,Battiato L,Jordan C,Slapak CA.A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy..Clin Cancer Res2004;10:3265-72

[105] Cripe LD,Paietta EM,Ketterling RP,Rowe JM,Luger S.Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999..Blood2010;116:4077-85 PMCID:PMC2993615

[106] Kühnle M,Müller C,Bernhardt G,König B.Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the P-glycoprotein (ABCB1) modulator tariquidar..J Med Chem2009;52:1190-7

[107] Li XQ,Lei Y,Zhang FL,To KK.Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives..Eur J Med Chem2015;101:560-72

[108] Kakarla P,Devireddy AR,Willmon TM,Shrestha U,Hernandez AJ,Varela MF.3D-QSAR and contour map analysis of tariquidar analogues as multidrug resistance protein-1 (MRP1) inhibitors..Int J Pharm Sci Res2016;7:554-72

[109] Kannan P,Shukla S,Pike VW,Gottesman MM,Hall MD.The "specific" P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2)..ACS Chem Neurosci2011;2:82-9 PMCID:PMC3369725

[110] Martin C,Mistry P,Charlton P.The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein..Br J Pharmacol1999;128:403-11 PMCID:PMC1571648

[111] Bankstahl JP,Römermann K,Stanek J,Fedrowitz M,Müller M,Langer O.Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and BCRP at the blood-brain barrier: a small-animal positron emission tomography and in vitro study..Drug Metab Dispos2013;41:754-62

[112] Weidner LD,Kannan P,Kumar JS,Innis RB,Hall MD.Tariquidar is an inhibitor and not a substrate of human and mouse P-glycoprotein..Drug Metab Dispos2016;44:275-82 PMCID:PMC4746486

[113] Mross K,Edler L,Queisser W,Goebel M.Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society..Ann Oncol1993;4:45-50

[114] Leonard GD,Bates SE.The role of ABC transporters in clinical practice..Oncologist2003;8:411-24

[115] Porcelli L,Peters GJ,Azzariti A.Intracellular trafficking of MDR transporters and relevance of SNPs..Curr Top Med Chem2009;9:197-208

[116] Follit CA,Wise JG.In silico identified targeted inhibitors of P-glycoprotein overcome multidrug resistance in human cancer cells in culture..Pharmacol Res Perspect2015;3:e00170

[117] Brewer FK,Vogel PD.In silico screening for inhibitors of p-glycoprotein that target the nucleotide binding domains..Mol Pharmacol2014;86:716-26 PMCID:PMC4244591

[118] Nanayakkara AK,Chen G,Vogel PD.Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells..Sci Rep2018;8:967 PMCID:PMC5772368

[119] Zinzi L,Cantore M,Leopoldo M.Small and innovative molecules as new strategy to revert MDR..Front Oncol2014;4:2 PMCID:PMC3896858

[120] Yang X,Singh A,Choy E,Amiji MM.Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer..Pharm Res2015;32:2097-109 PMCID:PMC4425596

[121] Ganesh S,Morrissey DV.Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors..Biomaterials2013;34:3489-502 PMCID:PMC3636539

[122] Wu D,Meng XN,Zong ZH.MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1..Tumour Biol2016;37:10499-506

[123] Zhu H,Liu X,Medina DJ,Yang JM.Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells..Biochem Pharmacol2008;76:582-8 PMCID:PMC2628586

[124] Da Silva CG,Ossendorp F.The potential of multi-compound nanoparticles to bypass drug resistance in cancer..Cancer Chemother Pharmacol2017;80:881-94 PMCID:PMC5676819

[125] Iwamoto T.Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs..Biol Pharm Bull2013;36:715-8

[126] Yamamoto Y,Iwase H.Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval..OncoTargets Ther2011;4:123-36 PMCID:PMC3143911

[127] Jin X,Xue L.Soluplus® micelles as a potential drug delivery system for reversal of resistant tumor..Biomed Pharmacother2015;69:388-95

[128] Win-Shwe TT.Nanoparticles and neurotoxicity..Int J Mol Sci2011;12:6267-80 PMCID:PMC3189781

[129] De Jong WH.Drug delivery and nanoparticles: applications and hazards..Int J Nanomedicine2008;3:133-49 PMCID:PMC2527668

[130] Zhou Y.Prediction value of miR-483 and miR-214 in prognosis and multidrug resistance of esophageal squamous cell carcinoma..Genet Test Mol Biomark2013;17:470-4 PMCID:PMC3668496

[131] Li Z,Wang J,Xiao L,Wang Z.MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells..Gynecol Oncol2010;119:125-30

[132] Chen Z,Huang C,Lv X,Hu T.MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells..Cell Signal2013;25:2693-701

[133] Feng DD,Zhang P,Zhang XJ,Luo XQ,Zhou H,Chen YQ.Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia..J Cell Mol Med2011;15:2164-75 PMCID:PMC4394226

[134] Hong L,Zhang H,Gong T,Wu K,Fan D.The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma..Ann Surg2010;251:1056-63

[135] Lee SD,Wasan KM.Dose-dependent targeted suppression of P-glycoprotein expression and function in Caco-2 cells..Mol Pharm2013;10:2323-30 PMCID:PMC3674641

[136] Bao L,Mehra S,Moroz K.Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298..Am J Pathol2012;180:2490-503 PMCID:PMC3378910

[137] Lin CJ,Tseng HC,Wu JL.miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines..Biochem Biophys Res Commun2008;375:315-20

[138] Xu Y,Li Z,Gong G,Mao Z,Fan JY.Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance..PLoS One2013;8:e82062

[139] Yang T,Li XN,Wang Y,Bai L.MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells..Exp Biol Med (Maywood)2013;238:1024-32

[140] Munoz JL,Greco SJ,Ligon KL.Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity..Mol Ther Nucleic Acids2013;2:e126

[141] Nobili S,Mazzei T.Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression..Med Res Rev2012;32:1220-62

[142] Stupp R,Bromberg JEC,Campone M,Frenay M,Wiesinger H,van den Bent MJ,van der Graaf W,Gorlia T,Brandes AA.Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group..Ann Oncol2011;22:2144-9 PMCID:PMC3164435

[143] Lee FY,Fairchild CR,Long BH,Vite GD,Kramer RA.BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy..Clin Cancer Res2001;7:1429-37

[144] Lechleider RJ,Jiang X,Bullock J,Harapanhalli R,Sridhara R,Booth B,Justice R.Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies..Clin Cancer Res2008;14:4378-84

[145] Puhalla S.Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer..Biol Targets Ther2008;2:505-15

[146] Sparano JA,Rixe O,Manikhas A,Ventilari Da Costa SC,Rubio G,Perez Manga G,Poulart V.Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane..J Clin Oncol2010;28:3256-63 PMCID:PMC2903325

[147] Mitchell D,Ferguson W,Higgins T,DeSarno M,Kraveka J,Vander Werff A,Sholler GL.A phase 1 trial of TPI 287 as a single agent and in combination with temozolomide in patients with refractory or recurrent neuroblastoma or medulloblastoma..Pediatr Blood Cancer2016;69:39-46

[148] Dumontet C,Lee FF.Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies..Mol Cancer Ther2009;8:17-25

[149] Shen H,Gan J.Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2)..J Pharmacol Exp Ther2011;337:423-32

[150] Yang CP,Wang F,He L,Höfle G,Orr GA.A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence..Mol Cancer Ther2005;4:987-95

[151] Wangari-Talbot J.Drug resistance mechanisms in non-small cell lung carcinoma..J Can Res Updat2014;2:265-82

[152] Hall MD,Gottesman MM.Is resistance useless? Multidrug resistance and collateral sensitivity..Trends Pharmacol Sci2009;30:546-56 PMCID:PMC2774243

[153] Bergman AM,Jensen PB,Veerman G,Smid K,Peters GJ.Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines..Biochem Pharmacol2001;61:1401-8

[154] Nakagawa-Goto K,Ohkoshi E,Lee KH.Antitumor agents 291 expanded B-Ring modification study of 6,8,8-triethyl desmosdumotin B analogues as multidrug-resistance selective agents..Med Chem2011;1:1000101 PMCID:PMC3537172

[155] Hall MD,Varonka MS,Monda JK,Walsh MJ,Warren TH,Gottesman MM.Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity towards multidrug-resistant cells expressing P-glycoprotein..J Med Chem2011;54:5878-89 PMCID:PMC3201829

[156] Vine KL,Jones L,Wade S,Ranson M.N-alkylated isatins evade P-gp mediated efflux and retain potency in MDR cancer cell lines..Heliyon2016;2:e00060

[157] Bergman AM,Talianidis I,Loves WJ,Peters GJ.Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines..Br J Cancer2003;88:1963-70 PMCID:PMC2741118

[158] Bergman AM,Peters GJ.Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells..Eur J Pharmacol2001;416:19-24

[159] Borner MM,de Wit R,Comella G,Greim G,van der Born K,de Boer RF,Fumoleau P.Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer..Eur J Cancer2002;38:349-58

[160] Liu G,Fitch MI.Patient preferences for oral versus intravenous palliative chemotherapy..J Clin Oncol1997;15:110-5

[161] Grant DS,Zahaczewsky M.Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)..Int J Cancer2003;104:121-9

[162] Kerbel RS.The anti-angiogenic basis of metronomic chemotherapy..Nat Rev Cancer2004;4:423-36

[163] Sparreboom A,Mayer U,Smit JW,Borst P,Beijnen JH.Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine..Proc Natl Acad Sci U S A1997;94:2031-5 PMCID:PMC20037

[164] van Asperen J,van der Valk MA,Beijnen JH.Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A..Clin Cancer Res1998;4:2293-7

[165] Bardelmeijer HA,Beijnen JH,van Tellingen O.Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice..Invest New Drugs2004;22:219-29

[166] Bardelmeijer HA,Brouwer KR,Nooijen WJ,van Tellingen O.Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein..Clin Cancer Res2000;6:4416-21

[167] Koolen SL,Schellens JH.Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel..Clin Pharmacol Ther2010;87:126-9

[168] Shukla S,Ambudkar SV.Improving cancer chemotherapy with modulators of ABC drug transporters..Curr Drug Targets2011;12:621-30 PMCID:PMC3401946

[169] Wils P,Warnery A,Raeissi S,Scherman D.Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers..Biochem Pharmacol1994;48:1528-30

[170] Jibodh RA,Nuijen B,Schellens JH.Taxanes: old drugs, new oral formulations..New Front Breast Cancer Treat2013;717:40-6

[171] Rezonja R,Cufer T.Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions..Radiol Oncol2013;47:1-13 PMCID:PMC3573828

[172] Hamada H.Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies..Proc Natl Acad Sci U S A1986;83:7785-9 PMCID:PMC386806

[173] Pearson JW,Volker K,Goldenberg SK,Riggs CW,Wiltrout RH.Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody..J Natl Cancer Inst1991;83:1386-91

[174] Naito M,Kuroko C,Tomida A,Heike Y.Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance..J Natl Cancer Inst1993;85:311-6

[175] Naito M.[18]Monoclonal antibodies to P-glycoprotein: preparation and applications to basic and clinical research..Methods Enzymol1998;292:258-65

[176] Cole SP.Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future..Annu Rev Pharmacol Toxicol2014;54:95-117

[177] Wang S,Li S,Geng P,Deng A.Indomethacin-based stimuli-responsive micelles combined with paclitaxel to overcome multidrug resistance..Oncotarget2017;8:111281-94

[178] Wan Y,Dronov R,Voelcker NH.Cancer-targeting siRNA delivery from porous silicon nanoparticles..Nanomedicine (Lond)2014;9:2309-21

[179] Wedge SR,Hennequin LF,Barry ST,Smith NR,Dukes M,Chester R,Boffey SJ,Barnett S,Wadsworth PF,Bigley AL,Cooper L,Jürgensmeier JM.AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer..Cancer Res2005;65:4389-400

[180] Tao LY,Wang F,Yan YY,Fu LW.Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function..Cancer Chemother Pharmacol2009;64:961-9

[181] Zheng L,Li Y,Chen L,Dai C,Tao L,Yang A,Fu L.Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function..PLoS One2009;4:e5172

[182] Mi Y.ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein..Br J Cancer2007;97:934-40 PMCID:PMC2360411

[183] Hegedus T,Seprodi A,Sarkadi B.Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1..Biochim Biophys Acta2002;1587:318-25

[184] Leier I,Buchholz U,Deeley RG.The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates..J Biol Chem1994;269:27807-10

[185] Minderman H,Pendyala L.VX-710 (Biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein..Clin Cancer Res2004;10:1826-34

[186] Katayama R,Sato S,Tsuruo T.Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export..Cancer Sci2009;100:2060-8

[187] Robey RW,Finley EM,Barnett D,Fojo T.Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®..Biochem Pharmacol2008;75:1302-12 PMCID:PMC2346578

[188] Ji L,Li S,Tang S,Meng X.A novel triazolonaphthalimide induces apoptosis and inhibits tumor growth by targeting DNA and DNA-associated processes..Oncotarget2017;8:37394-408 PMCID:PMC5514917

[189] Saeki T,Toi M,Noguchi S,Asaga T,Yamamoto N,Ikeda T,Sato W.Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer..J Clin Oncol2007;25:411-7

[190] Cole SP.Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter..J Biol Chem2014;289:30880-8 PMCID:PMC4223294

[191] Trompier D,Barattin R,Di Pietro A.Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1..Cancer Res2004;64:4950-6

[192] de Groot DJA,Le TK,de Jong S.Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1..Br J Cancer2007;97:1077-83 PMCID:PMC2360450

[193] Ahmed-Belkacem A,Macalou S,Boumendjel A.Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2)..Anticancer Drugs2006;17:239-43

[194] Rabindran SK,Singh M,Collins KI,Greenberger LM.Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C..Cancer Res1998;58:5850-8

[195] Allen JD,Lakhai JM,van Tellingen O,Schellens JH,Schinkel AH.Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C..Mol Cancer Ther2002;1:417-25

[196] Pick A,Wiese M.Specific inhibitors of the breast cancer resistance protein (BCRP)..Chem Med Chem2010;5:1498-505

[197] Peng H,Qi J,Liu Y,Xu J.A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy..PLoS One2009;4:e5676

[198] Komeili-Movahhed T,Barzegar E,Hossein Ghahremani M,Madjd Z.PI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7 breast cancer cell line to mitoxantrone chemotherapy..Iran J Basic Med Sci2015;18:472-7

[199] Singh MS,Wiese M.Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation..Eur J Pharm Sci2015;77:1-8

[200] Li WQ,Tao BB,Hu GH,He J,Yu HY.Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance..Med Sci Monit2010;16:HY27-30

[201] Li X,Seigel GM,Huang M.Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells..Biochem Pharmacol2011;81:783-92 PMCID:PMC3042498

[202] Turrini E,Laechelt S,Bruhn O.MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression..Pharmacogenet Genomics2012;22:198-205

[203] Jiao X,Ma M,He M,Wang Y,Zhao X,Cui Z,Wang E.MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2)..Breast Cancer Res Treat2013;139:717-30

[204] Ma MT,Wang Y,Zhao L,Yu ZJ,Sun ML,Wei MJ.MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2)..Cancer Lett2013;339:107-15

[205] Wang Y,Xiao Q,He M,Ma M,Wei M.miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells..Gynecol Oncol2016;141:592-601

[206] Zhang L,Zhang D,Qin L,Zhang L.Upregulated miR-132 in Lgr5+gastric cancer stem cell-like cells contributes to cisplatin-resistance via SIRT1/CREB/ABCG2 signaling pathway..Mol Carcinog2017;56:2022-34

[207] Chen B,Kuai J,Fang X.Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/β-catenin-ABCG2 signaling pathway in ALDHA1+colorectal cancer stem cells..Tumour Biol2017;39:1010428317715155

[208] Shukla S,Ambudkar SV.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance..Drug Resist Updat2012;15:70-80 PMCID:PMC3348341

[209] Azzariti A,Simone GM,Colabufo NA,Perrone R,D'Incalci M,Paradiso A.Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences..Cancer Chemother Pharmacol2010;65:335-46

[210] Ozvegy-Laczka C,Várady G,Schuetz JD,Kéri G,Német K.High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter..Mol Pharmacol2004;65:1485-95

[211] Veronese ML,Giantonio B,Shults J,Haller DG.A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer..Br J Cancer2005;92:1846-9 PMCID:PMC2361767

[212] Deenik W,van der Holt B,Smit WM,Daenen SM,Ferrant A,Sonneveld P,Wittebol S,Wijermans PW,Löwenberg B,Ossenkoppele GJ.Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia..Haematologica2010;95:914-21 PMCID:PMC2878788

[213] Fukuoka M,Giaccone G,Nakagawa K,Nishiwaki Y,Kudoh S,Eek R,Noda K,Smit E,Macleod A,Dong RP.Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]..J Clin Oncol2003;21:2237-46

[214] Giaccone G,van Oosterom AT,Smit EF,Peters GJ,Smith R,Fandi A.Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors..Ann Oncol2004;15:831-8

[215] Stewart CF,Schuetz JD,Cheshire PJ,Daw N,Gilbertson R,Harwood FC.Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice..Cancer Res2004;64:7491-9

[216] Leggas M,Zhuang Y,Johnston B,Sorrentino B,Houghton PJ.Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo..Cancer Res2006;66:4802-7

[217] Nishino H.Cancer prevention by carotenoids..Mutat Res1998;402:159-63

[218] Leslie EM,Oleschuk CJ,Cole SP.Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids..Mol Pharmacol2001;59:1171-80

[219] Alvarez AI,Pérez M,Prieto JG.Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response..J Pharm Sci2010;99:598-617

[220] Cooray HC,van Veen HW,Barrand MA.Interaction of the breast cancer resistance protein with plant polyphenols..Biochem Biophys Res Commun2004;317:269-75

[221] Pan L,Wang X,Jiang H,Lou Y.Inhibitory effects of neochamaejasmin B on P-glycoprotein in MDCK-hMDR1 cells and molecular docking of NCB binding in P-glycoprotein..Molecules2015;20:2931-48

[222] Forester SC.Metabolites are key to understanding health effects of wine polyphenolics..J Nutr2009;139:S1824-31

[223] Bohn T,Alegría A,Arrigoni E,Brito C,El SN,Martínez-Cuesta MC.Mind the gap-deficits in our knowledge of aspects impacting the bioavailability of phytochemicals and their metabolites--a position paper focusing on carotenoids and polyphenols..Mol Nutr Food Res2015;59:1307-23 PMCID:PMC5033009